Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 8/20 | 0.46 |
| ▸ | SYK | P43405 | 7/20 | 0.44 |
| ▸ | CCND3 | P30281 | 2/20 | 0.42 |
| ▸ | CCNK | O75909 | 1/20 | 0.42 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.42 |
| ▸ | CDK2 | P24941 | 1/20 | 0.42 |
| ▸ | CDK9 | P50750 | 1/20 | 0.42 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.42 |
| ▸ | CDK4 | P11802 | 1/20 | 0.41 |
| ▸ | CCND1 | P24385 | 1/20 | 0.41 |
| ▸ | CCND2 | P30279 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.39 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
| ▸ | JAK1 | P23458 | 1/20 | 0.39 |
| ▸ | TYK2 | P29597 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6073369 | 1.00 | JAK3 (0.46) | JAK3SYKCCND3CCNKCCNA2 | |
| SCHEMBL6073544 | 0.88 | CCND3 (0.46) | JAK3SYKCCND3CCNKCCNA2 | |
| SCHEMBL6073540 | 0.88 | CCND3 (0.46) | JAK3SYKCCND3CCNKCCNA2 | |
| SCHEMBL6074009 | 0.86 | SYK (0.42) | JAK3SYKCCND3CCNKCCNA2 | |
| SCHEMBL6073774 | 0.86 | JAK3 (0.43) | JAK3SYKCCND3CCNKCCNA2 | |
| SCHEMBL6073785 | 0.86 | JAK3 (0.43) | JAK3SYKCCND3CCNKCCNA2 | |
| SCHEMBL6074012 | 0.86 | SYK (0.42) | JAK3SYKCCND3CCNKCCNA2 | |
| SCHEMBL6073388 | 0.85 | SYK (0.40) | JAK3SYKCCND3CCNKCCNA2 | |
| SCHEMBL6073385 | 0.85 | SYK (0.40) | JAK3SYKCCND3CCNKCCNA2 | |
| SCHEMBL6074010 | 0.84 | CDK2 (0.59) | JAK3SYKCCND3CCNKCCNA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7053070-B2 | Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors | WARNER-LAMBERT COMPANY (US) | 2006-05-30 | — | — | US | disclosed |
| US-20030073668-A1 | Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors | BOOTH RICHARD JOHN (US) | 2003-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030073668-A1 | Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors | CDK9, CDK19, CDK3 | JAK3 254/4885SYK 1176/4885CCND3 98/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.